| Date | Title | Description | |
|---|---|---|---|
| 27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
| 08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
| 26 Jul 2023 | On P&L | The Company releases the press release related to the first half 2023 financial results | Download |
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 11 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 3 August and 10 August 2023 | Download |
| 03 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 | Download |
| 28 Jul 2023 | On business and financial situation | ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® | Download |
| 05 Jul 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2023 | Download |
| 26 Jun 2023 | Other relevant information | The Company informs about the dividends payment | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
| 21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
| 08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
| 24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |